Inovio
Pre-Approval PRO BETAStale Activity
No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 10/1/2022
Pipeline by Phase
Therapeutic Focus
Clinical Trials (27)
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Started: 2/28/2019
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Started: 6/28/2017
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Started: 6/21/2021
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Started: 11/30/2020
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Started: 8/31/2017
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Started: 5/15/2018
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Started: 4/1/2011
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Started: 10/7/2020
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Started: 5/31/2018
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Started: 5/24/2018
Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
Started: 1/27/2021
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
Started: 10/1/2022
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
Started: 4/3/2020
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
Started: 6/6/2014
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
Started: 8/13/2014
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
Started: 5/9/2019
Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
Started: 1/12/2015
Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Started: 5/1/2015
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Started: 12/1/2014
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
Started: 5/1/2014
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
Started: 7/1/2010
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
Started: 7/1/2015
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
Started: 5/1/2008
Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults
Started: 6/1/2010
A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
Started: 5/1/2011
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
Started: 5/1/2011
Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
Started: 1/1/2011